Today, NCI and many collaborators launched a unique clinical trial for people with a form of lung cancer. The study, LungMAP, will match participants to one of several different investigational treatments based on the genomic profiles of their tumors: http://1.usa.gov/1qkzdgB
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research, the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial.
Filed under: cancer Tagged: Lung Cancer Master Protocol (Lung-MAP
